Estados Unidos · Plataformas y datos · TipRanks

Pfizer announces results across serotypes in Phase 2 study of 25vPnC

Publicado por TipRanks · Estados Unidos hace 9 h

Pfizer (PFE) announced detailed results across serotypes from a Phase 2 study for its investigational 25-valent pneumococcal conjugate vaccine candidate, ...

Leer el artículo completo en TipRanks Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.tipranks.com)

Pfizer announces results across serotypes in Phase 2 study of 25vPnC

También te puede interesar

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

Down 17%, Is Meta a Buy on the Dip?

Johnson & Johnson reports response rate for head, neck cancer treatment

Goldman lists 3 factors that support long commodities positions

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Samsung’s Galaxy Fit 4 could undercut Fitbit by $120

Pfizer announces results across serotypes in Phase 2 study of 25vPnC

Compartir

También te puede interesar

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

Down 17%, Is Meta a Buy on the Dip?

Johnson & Johnson reports response rate for head, neck cancer treatment

Goldman lists 3 factors that support long commodities positions

‘She’s living the dream’: My stepmother said I can buy my childhood home for $850,000. Is she taking advantage of me?

Samsung’s Galaxy Fit 4 could undercut Fitbit by $120